(NASDAQ: IOVA) Iovance Biotherapeutics's forecast annual revenue growth rate of 49.87% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.96%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.07%.
Iovance Biotherapeutics's revenue in 2026 is $250,425,000.On average, 14 Wall Street analysts forecast IOVA's revenue for 2026 to be $166,968,697,862, with the lowest IOVA revenue forecast at $132,269,727,604, and the highest IOVA revenue forecast at $225,247,565,537. On average, 11 Wall Street analysts forecast IOVA's revenue for 2027 to be $253,515,654,681, with the lowest IOVA revenue forecast at $178,953,160,876, and the highest IOVA revenue forecast at $322,345,930,999.
In 2028, IOVA is forecast to generate $332,845,733,806 in revenue, with the lowest revenue forecast at $227,581,737,201 and the highest revenue forecast at $400,540,681,730.